• 1

    Jemal A, Siegel R, Ward E et al. . Cancer statistics, 2009. CA Cancer J Clin 2009;59:225229.

  • 2

    Greene F, Page D, Fleming I, Fritz A. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.

  • 3

    Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004;41:801807.

    • Search Google Scholar
    • Export Citation
  • 4

    Ahsan H, Neugut AI, Garbowski GC et al. . Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998;128:900905.

    • Search Google Scholar
    • Export Citation
  • 5

    Bonelli L, Martines H, Conio M et al. . Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988;41:513517.

    • Search Google Scholar
    • Export Citation
  • 6

    Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295308.

  • 7

    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:14201425.

    • Search Google Scholar
    • Export Citation
  • 8

    Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst 2004;96:14081409.

  • 9

    Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:10161025.

    • Search Google Scholar
    • Export Citation
  • 10

    Compton CC, Fielding LP, Burgart LJ et al. . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979994.

    • Search Google Scholar
    • Export Citation
  • 11

    Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416421.

    • Search Google Scholar
    • Export Citation
  • 12

    Sobin LH, Greene FL. TNM classification. Clarification of number of regional lymph nodes for pN0. Cancer 2001;92:452.

  • 13

    Sarli L, Bader G, Iusco D et al. . Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005;41:272279.

  • 14

    Le Voyer T, Sigurdson E, Hamlin A et al. . Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:29122919.

    • Search Google Scholar
    • Export Citation
  • 15

    Bilimoria K, Palis B, Stewart AK et al. . Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 2008;51:154161.

  • 16

    Newland RC, Dent OF, Lyttle MN et al. . Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994;73:20762082.

    • Search Google Scholar
    • Export Citation
  • 17

    Chapuis PH, Dent OF, Bokey EL et al. . Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg 2004;91:349354.

    • Search Google Scholar
    • Export Citation
  • 18

    Wong SL, Hong J, Hollenbeck BK et al. . Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298:21492154.

    • Search Google Scholar
    • Export Citation
  • 19

    Redston M, Compton CC, Miedema BW et al. . Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B trial 80001. J Clin Oncol 2006;24:878883.

    • Search Google Scholar
    • Export Citation
  • 20

    Saha S, Van A, Beutler T et al. . Sentinel lymph mapping techniques in colorectal cancer. Semin Oncol 2004;31:374381.

  • 21

    Wiese DA, Saha S, Badin J et al. . Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma. Arch Pathol Lab Med 2000;124:17591763.

  • 22

    Bertagnolli M, Miedema B, Redston M et al. . Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004;240:624628; discussion 628–630.

    • Search Google Scholar
    • Export Citation
  • 23

    Noura S, Yamamoto H, Miyake Y et al. . Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759767.

    • Search Google Scholar
    • Export Citation
  • 24

    Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008;26:15821584.

  • 25

    Amado RG, Wolf M, Peeters M et al. . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 26

    Khambata-Ford S, Garrett CR, Meropol NJ et al. . Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:32303237.

    • Search Google Scholar
    • Export Citation
  • 27

    De Roock W, Piessevaux H, De Schutter J et al. . KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508515.

    • Search Google Scholar
    • Export Citation
  • 28

    Punt CJ, Tol J, Rodenburg CJ et al. . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract LBA 4011.

    • Search Google Scholar
    • Export Citation
  • 29

    Bokemeyer C, Bondarenko I, Makhson A et al. . Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663771.

    • Search Google Scholar
    • Export Citation
  • 30

    Tejpar S, Peeters M, Humblet Y et al. . Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4001.

    • Search Google Scholar
    • Export Citation
  • 31

    Van Cutsem E, Henning-Kohne C, Hitre E et al. . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 36014:14081417.

    • Search Google Scholar
    • Export Citation
  • 32

    Lièvre A, Bachet JB, Boige V et al. . KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 33

    Karapetis CS, Khambata-Ford S, Jonker DJ et al. . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:17571765.

    • Search Google Scholar
    • Export Citation
  • 34

    Lievre A, Bachet J-B, Boige V et al. . KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol 2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 35

    Artale S, Sartore-Bianchi A, Veronese SM et al. . Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:42174219.

    • Search Google Scholar
    • Export Citation
  • 36

    Etienne-Grimaldi MC, Formento JL, Francoual M et al. . KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res 2008;14:48304835.

    • Search Google Scholar
    • Export Citation
  • 37

    Cooper HS, Deppisch LM, Gourley WK et al. . Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995;108:16571665.

    • Search Google Scholar
    • Export Citation
  • 38

    Markowitz AJ, Winawer SJ. Management of colorectal polyps. CA Cancer J Clin 1997;47:93112.

  • 39

    Nivatvongs S, Rojanasakul A, Reiman HM et al. . The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum 1991;34:323328.

    • Search Google Scholar
    • Export Citation
  • 40

    Volk EE, Goldblum JR, Petras RE et al. . Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995;109:18011807.

    • Search Google Scholar
    • Export Citation
  • 41

    Ueno H, Mochizuki H, Hashiguchi Y et al. . Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385394.

    • Search Google Scholar
    • Export Citation
  • 42

    Seitz U, Bohnacker S, Seewald S et al. . Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004;47:17891796.

    • Search Google Scholar
    • Export Citation
  • 43

    Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89:328336.

    • Search Google Scholar
    • Export Citation
  • 44

    Crawley J, Petras R, Carey W et al. . When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive cancer? Gastroenterology 1986;91:419427.

    • Search Google Scholar
    • Export Citation
  • 45

    Winawer SJ, Fletcher RH, Miller L et al. . Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594642.

  • 46

    Balthazar EJ, Megibow AJ, Hulnick D, Naidich DP. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 1988;150:301306.

    • Search Google Scholar
    • Export Citation
  • 47

    Cohen AM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol 1991;18:381387.

  • 48

    Joseph NE, Sigurdson ER, Hanlon AL et al. . Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003;10:213218.

    • Search Google Scholar
    • Export Citation
  • 49

    Berger AC, Sigurdson ER, LeVoyer T et al. . Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:87068712.

    • Search Google Scholar
    • Export Citation
  • 50

    Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006;24:35703575.

    • Search Google Scholar
    • Export Citation
  • 51

    Lacy AM, Garcia-Valdecasas JC, Delgado S et al. . Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002;359:22242229.

    • Search Google Scholar
    • Export Citation
  • 52

    Buunen M, Veldkamp R, Hop WC et al. . Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 2009;10:4452.

    • Search Google Scholar
    • Export Citation
  • 53

    Jayne DG, Guillou, Thorpe H et al. . Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol 2007;25:30613068.

    • Search Google Scholar
    • Export Citation
  • 54

    Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004;350:20502059.

    • Search Google Scholar
    • Export Citation
  • 55

    Fleshman J, Sargent DJ, Green E et al. . Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann Surg 2007;246:655664.

    • Search Google Scholar
    • Export Citation
  • 56

    Kuhry E, Schwenk W, Gaupset R et al. . Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;CD003432.

  • 57

    Bonjer HJ, Hop WC, Nelson H et al. . Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg 2007;142:298303.

  • 58

    Jackson TD, Kaplan GG, Arena G et al. . Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg 2007;204:439446.

    • Search Google Scholar
    • Export Citation
  • 59

    Kuhry E, Bonjer HJ, Haglind E et al. . Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc 2005;19:687692.

    • Search Google Scholar
    • Export Citation
  • 60

    Kienle P, Weitz J, Koch M, Buchler MW. Laparoscopic surgery for colorectal cancer. Colorectal Dis 2006;8(Suppl 3):3336.

  • 61

    Wagman LJ. Laparoscopic and open surgery for colorectal cancer: reaching equipoise? J Clin Oncol 2007;25:29962998.

  • 62

    Wishner JD, Baker JW Jr, Hoffman GC et al. . Laparoscopic-assisted colectomy. The learning curve. Surg Endosc 1995;9:11791183.

  • 63

    Nelson H, Weeks JC, Wieand HS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr 1995;19:5156.

    • Search Google Scholar
    • Export Citation
  • 64

    Ota D, Nelson H, Weeks J et al. . Controversies regarding laparoscopic colectomy for malignant diseases. Curr Opin Gen Surg 1994:208213.

  • 65

    Sun W, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol 2005;32:95102.

  • 66

    Baddi L, Benson A III. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005;10:325331.

  • 67

    Benson AB III. New approaches to the adjuvant therapy of colon cancer. Oncologist 2006;11:973980.

  • 68

    Andre T, Boni C, Mounedji-Boudiaf L et al. . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:23432351.

    • Search Google Scholar
    • Export Citation
  • 69

    de Gramont A, Boni C, Navarro M et al. . Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3501.

    • Search Google Scholar
    • Export Citation
  • 70

    de Gramont A, Boni C, Navarro M et al. . Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4007.

    • Search Google Scholar
    • Export Citation
  • 71

    Sargent DJ, Wieand HS, Haller DG et al. . Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:86648670.

    • Search Google Scholar
    • Export Citation
  • 72

    Sargent DJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient ACCENT dataset [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4008.

    • Search Google Scholar
    • Export Citation
  • 73

    Sargent D, Sobrero A, Grothey A et al. . Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872877.

    • Search Google Scholar
    • Export Citation
  • 74

    Andre T, Boni C, Navarro M et al. . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:31093116.

    • Search Google Scholar
    • Export Citation
  • 75

    Saltz L, Niedzwiecki D, Hollis D et al. . Irinotecan fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:34563461.

    • Search Google Scholar
    • Export Citation
  • 76

    Rothenberg ML, Meropol NJ, Poplin EA et al. . Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:38013807.

    • Search Google Scholar
    • Export Citation
  • 77

    Van Cutsem E, Labianca R, Bodoky G et al. . Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:31173125.

    • Search Google Scholar
    • Export Citation
  • 78

    Ychou M, Raoul JL, Douillard JY et al. . A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20:674680.

    • Search Google Scholar
    • Export Citation
  • 79

    Wolmark N, Wieand H, Kuebler J et al. . A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3500.

    • Search Google Scholar
    • Export Citation
  • 80

    Kuebler JP, Wieand S, O’Connell MJ et al. . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:21982204.

    • Search Google Scholar
    • Export Citation
  • 81

    Twelves C, Wong A, Nowacki MP et al. . Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:26962704.

  • 82

    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939944.

    • Search Google Scholar
    • Export Citation
  • 83

    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:13561363.

    • Search Google Scholar
    • Export Citation
  • 84

    Gill S, Loprinzi CL, Sargent DJ et al. . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:17971806.

    • Search Google Scholar
    • Export Citation
  • 85

    Schrag D, Rifas-Shiman S, Saltz L et al. . Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:39994005.

    • Search Google Scholar
    • Export Citation
  • 86

    Wolmark N, Rockette H, Mamounas E et al. . Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:35533559.

    • Search Google Scholar
    • Export Citation
  • 87

    Haller DG, Catalano PJ, Macdonald JS et al. . Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23:86718678.

    • Search Google Scholar
    • Export Citation
  • 88

    Quasar Collaborative Group Gray R, Barnwell J, McConkey C et al. . Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:20202029.

    • Search Google Scholar
    • Export Citation
  • 89

    Benson AB III, Schrag D, Somerfield MR et al. . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:34083419.

    • Search Google Scholar
    • Export Citation
  • 90

    Love N, Bylund C, Meropol NJ et al. . How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4200.

    • Search Google Scholar
    • Export Citation
  • 91

    Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer 2005;92:18191824.

    • Search Google Scholar
    • Export Citation
  • 92

    Benson AB III. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal appro0aches in early-stage disease. Clin Cancer Res 2007;13:6913s6920s.

    • Search Google Scholar
    • Export Citation
  • 93

    Van Cutsem E, Nordlinger B, Adam R et al. . Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:22122221.

    • Search Google Scholar
    • Export Citation
  • 94

    Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202207.

    • Search Google Scholar
    • Export Citation
  • 95

    Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20:11611176, 1179; discussion 1179–1180, 1185–1166.

    • Search Google Scholar
    • Export Citation
  • 96

    Muratore A, Zorzi D, Bouzari H et al. . Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766770.

    • Search Google Scholar
    • Export Citation
  • 97

    Alberts SR, Horvath WL, Sternfeld WC et al. . Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:92439249.

    • Search Google Scholar
    • Export Citation
  • 98

    Fong Y, Cohen AM, Fortner JG et al. . Liver resection for colorectal metastases. J Clin Oncol 1997;15:938946.

  • 99

    Tsai M, Su Y, Ho M et al. . Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol 2007;14:786794.

    • Search Google Scholar
    • Export Citation
  • 100

    Poultsides GA, Servais EL, Saltz LB et al. . Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:33793384.

    • Search Google Scholar
    • Export Citation
  • 101

    Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis 1984;4:170179.

  • 102

    Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J.. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:14051410.

    • Search Google Scholar
    • Export Citation
  • 103

    Venook AP. The Kemeny article reviewed. Oncology 2006;20:477484.

  • 104

    Choti MA, Sitzmann JV, Tiburi MF et al. . Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759766.

    • Search Google Scholar
    • Export Citation
  • 105

    Pawlik TM, Scoggins CR, Zorzi D et al. . Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715722.

    • Search Google Scholar
    • Export Citation
  • 106

    Charnsangavej C, Clary B, Fong Y et al. . Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:12611268.

    • Search Google Scholar
    • Export Citation
  • 107

    Vauthey JN, Zorzi D, Pawlik TM. Making unresectable hepatic colorectal metastases resectable--does it work? Semin Oncol 2005;32(Suppl 9):S118122.

    • Search Google Scholar
    • Export Citation
  • 108

    Pozzo C, Basso M, Cassano A et al. . Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933939.

    • Search Google Scholar
    • Export Citation
  • 109

    Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003;12:165192.

    • Search Google Scholar
    • Export Citation
  • 110

    Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:5164.

  • 111

    Folprecht G, Grothey A, Alberts S et al. . Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:13111319.

    • Search Google Scholar
    • Export Citation
  • 112

    Reddy SK, Pawlik TM, Zorzi D et al. . Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007;14:34813491.

    • Search Google Scholar
    • Export Citation
  • 113

    Covey AM, Brown KT, Jarnagin WR et al. . Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008;247:451455.

    • Search Google Scholar
    • Export Citation
  • 114

    Adam R, Miller R, Pitombo M et al. . Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 2007;16:525536.

    • Search Google Scholar
    • Export Citation
  • 115

    Abdalla EK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg 2009;197:737739.

    • Search Google Scholar
    • Export Citation
  • 116

    Abdalla EK, Vauthey JN, Ellis LM et al. . Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818825.

    • Search Google Scholar
    • Export Citation
  • 117

    Hur H, Ko YT, Min BS et al. . Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197:728736.

    • Search Google Scholar
    • Export Citation
  • 118

    Gleisner AL, Choti MA, Assumpcao L et al. . Colorectal liver metastases: recurrence and survival following hepatic resectin, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008;143:12041212.

    • Search Google Scholar
    • Export Citation
  • 119

    Reuter NP, Woodall CE, Scoggins CR et al. . Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 2009;13:486491.

    • Search Google Scholar
    • Export Citation
  • 120

    Bilchik AJ, Poston G, Adam R, Choti MA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol 2008;26:53205321.

    • Search Google Scholar
    • Export Citation
  • 121

    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:20382048.

    • Search Google Scholar
    • Export Citation
  • 122

    Benoist S, Brouquet A, Penna C et al. . Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:39393945.

    • Search Google Scholar
    • Export Citation
  • 123

    Bilchik AJ, Poston G, Curley SA et al. . Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005;23:90739078.

  • 124

    Adam R, Avisar E, Ariche A et al. . Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol 2001;8:347353.

    • Search Google Scholar
    • Export Citation
  • 125

    Rivoire M, De Cian F, Meeus P et al. . Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:22832292.

    • Search Google Scholar
    • Export Citation
  • 126

    Vauthey JN, Pawlik TM, Ribero D et al. . Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:20652072.

    • Search Google Scholar
    • Export Citation
  • 127

    Pawlik TM, Olino K, Gleisner AL et al. . Preoperative chemotheapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11:860888.

    • Search Google Scholar
    • Export Citation
  • 128

    Pawlik TM, Poon RT, Abdalla EK et al. . Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450457; discussion 457–458.

    • Search Google Scholar
    • Export Citation
  • 129

    Elias D, Liberale G, Vernerey D et al. . Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900909.

    • Search Google Scholar
    • Export Citation
  • 130

    Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999;26:514523.

  • 131

    Adam R, Delvart V, Pascal G et al. . Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644657.

    • Search Google Scholar
    • Export Citation
  • 132

    Delaunoit T, Alberts SR, Sargent DJ et al. . Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005;16:425429.

    • Search Google Scholar
    • Export Citation
  • 133

    Nordlinger B, Sorbye H, Glimelius B et al. . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 2008;37:10071016.

    • Search Google Scholar
    • Export Citation
  • 134

    Tan BR, Zubal B, Hawkins w et al. . Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Gastrointestinal Cancers Symposium 2009; Abstract 497.

    • Search Google Scholar
    • Export Citation
  • 135

    Folprecht G, Gruenberger T, Hartmann JT et al. . Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 296.

    • Search Google Scholar
    • Export Citation
  • 136

    Souglakos J, Androulakis N, Syrigos K et al. . FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer 2006;94:798805.

    • Search Google Scholar
    • Export Citation
  • 137

    Falcone A, Ricci S, Brunetti I et al. . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:16701676.

    • Search Google Scholar
    • Export Citation
  • 138

    Scappaticci FA, Fehrenbacher L, Cartwright T et al. . Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173180.

    • Search Google Scholar
    • Export Citation
  • 139

    Package Insert. Bevacizumab (Avastin®). South San Francisco, CA, Genentech, Inc. October 2006.

  • 140

    Gruenberger B, Tamandl D, Schueller J et al. . Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:18301835.

    • Search Google Scholar
    • Export Citation
  • 141

    Reddy SK, Morse MA, Hurwitz HI et al. . Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96106.

    • Search Google Scholar
    • Export Citation
  • 142

    Rubbia-Brandt L, Audard V, Sartoretti P et al. . Severe hepatic sinusoidal obstructjion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460466.

    • Search Google Scholar
    • Export Citation
  • 143

    Zorzi D, Kishi Y, Maru DM et al. . Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 295.

    • Search Google Scholar
    • Export Citation
  • 144

    Lee WS, Yun SH, Chun HK et al. . Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007;22:699704.

    • Search Google Scholar
    • Export Citation
  • 145

    Headrick JR, Miller DL, Nagorney DM et al. . Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975979; discussion 979–980.

    • Search Google Scholar
    • Export Citation
  • 146

    Mitry E, Fields ALA, Bleiberg H et al. . Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:49064911.

    • Search Google Scholar
    • Export Citation
  • 147

    Kemeny N, Huang Y, Cohen AM et al. . Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:20392048.

    • Search Google Scholar
    • Export Citation
  • 148

    Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005;352:734735.

  • 149

    Mulcahy MF, Lewandowski RJ, Ibrahim SM et al. . Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009;115:18491858.

    • Search Google Scholar
    • Export Citation
  • 150

    Hong K, McBride JD, Georgiades CS et al. . Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009;20:360367.

    • Search Google Scholar
    • Export Citation
  • 151

    Katz AW, Carey-Sampson M, Muhs AG et al. . Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007;67:793798.

    • Search Google Scholar
    • Export Citation
  • 152

    Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004;34:209223.

  • 153

    Bartlett DL, Berlin J, Lauwers GY et al. . Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:12841292.

    • Search Google Scholar
    • Export Citation
  • 154

    Yan TD, Black D, Savady R, Sugarbaker PH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:40114019.

    • Search Google Scholar
    • Export Citation
  • 155

    Esquivel J, Sticca R, Sugarbaker P et al. . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128133.

    • Search Google Scholar
    • Export Citation
  • 156

    Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007;33:16.

    • Search Google Scholar
    • Export Citation
  • 157

    Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:45534560.

    • Search Google Scholar
    • Export Citation
  • 158

    Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981987.

  • 159

    Goldberg RM, Rothenberg ML, Van Cutsem E et al. . The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:3850.

    • Search Google Scholar
    • Export Citation
  • 160

    Goldberg RM, Sargent DJ, Morton RF et al. . Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:33473353.

    • Search Google Scholar
    • Export Citation
  • 161

    Douillard JY, Cunningham D, Roth AD et al. . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:10411047.

    • Search Google Scholar
    • Export Citation
  • 162

    Fuchs CS, Moore MR, Harker G et al. . Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807814.

    • Search Google Scholar
    • Export Citation
  • 163

    Petrelli N, Herrera L, Rustum Y et al. . A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:15591565.

    • Search Google Scholar
    • Export Citation
  • 164

    Van Cutsem E, Twelves C, Cassidy J et al. . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:40974106.

    • Search Google Scholar
    • Export Citation
  • 165

    Van Cutsem E, Hoff PM, Harper P et al. . Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:11901197.

    • Search Google Scholar
    • Export Citation
  • 166

    Buroker TR, O’Connell MJ, Wieand HS et al. . Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:1420.

    • Search Google Scholar
    • Export Citation
  • 167

    de Gramont A, Bosset JF, Milan C et al. . Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808815.

    • Search Google Scholar
    • Export Citation
  • 168

    Maindrault-Goebel F, Louvet C, Andre T et al. . Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:13381342.

    • Search Google Scholar
    • Export Citation
  • 169

    Van Cutsem E, Peeters M, Siena S et al. . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:16581664.

    • Search Google Scholar
    • Export Citation
  • 170

    Cunningham D, Humblet Y, Siena S et al. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 171

    van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:10101017.

  • 172

    Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(Suppl 5):412.

    • Search Google Scholar
    • Export Citation
  • 173

    O’Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006;11:992998.

  • 174

    Lentz F, Tran A, Rey E et al. . Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 2005;5:2133.

    • Search Google Scholar
    • Export Citation
  • 175

    Rothenberg ML, Blanke CD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999;26:632639.

  • 176

    Goldberg RM, Sargent DJ, Morton RF et al. . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 177

    Tournigand C, Andre T, Achille E et al. . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 178

    Delaunoit T, Goldberg RM, Sargent DJ et al. . Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004;101:21702176.

    • Search Google Scholar
    • Export Citation
  • 179

    Cheeseman SL, Joel SP, Chester JD et al. . A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393399.

    • Search Google Scholar
    • Export Citation
  • 180

    de Gramont A, Figer A, Seymour M et al. . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 181

    Colucci G, Gebbia V, Paoletti G et al. . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:48664875.

    • Search Google Scholar
    • Export Citation
  • 182

    Cassidy J, Clarke S, Diaz-Rubio D et al. . XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 270.

    • Search Google Scholar
    • Export Citation
  • 183

    Cassidy J, Tabernero J, Twelves C et al. . XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:20842091.

    • Search Google Scholar
    • Export Citation
  • 184

    Porschen R, Arkenau HT, Kubicka S et al. . Phase III study of capecitabine plus oxaliplatin compared with fluororuracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:42174223.

    • Search Google Scholar
    • Export Citation
  • 185

    Andre T, Louvet C, Maindrault-Goebel F et al. . CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:13431347.

    • Search Google Scholar
    • Export Citation
  • 186

    Jager E, Heike M, Bernhard H et al. . Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 187

    Wolmark N, Rockette H, Fisher B et al. . The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:18791887.

    • Search Google Scholar
    • Export Citation
  • 188

    Saltz LB, Clarke S, Díaz-Rubio E et al. . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:20132039.

    • Search Google Scholar
    • Export Citation
  • 189

    Saltz LB, Clarke S, Diaz-Rubio E et al. . Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 238.

    • Search Google Scholar
    • Export Citation
  • 190

    Kabbinavar FF, Schulz J, McCleod M et al. . Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:36973705.

    • Search Google Scholar
    • Export Citation
  • 191

    Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. . Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:35023508.

    • Search Google Scholar
    • Export Citation
  • 192

    Hochster HS, Hart LL, Ramanathan RK et al. . Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529. Erratum in: J Clin Oncol 2008;26:4697.

    • Search Google Scholar
    • Export Citation
  • 193

    Kabbinavar FF, Hambleton J, Mass RD et al. . Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:37063712.

    • Search Google Scholar
    • Export Citation
  • 194

    Hurwitz H, Fehrenbacher L, Novotny W et al. . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 195

    Fuchs CS, Marshall J, Mitchell EP et al. . Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 276.

    • Search Google Scholar
    • Export Citation
  • 196

    Fuchs CJ, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007;24:47794786.

    • Search Google Scholar
    • Export Citation
  • 197

    Sobero A, Ackland S, Carrion R et al. . Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 3544.

    • Search Google Scholar
    • Export Citation
  • 198

    Giantonio B, Catalano P, Meropol N et al. . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25:15391544.

    • Search Google Scholar
    • Export Citation
  • 199

    Cannistra SA, Matulonis UA, Penson RT et al. . Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:51505152.

    • Search Google Scholar
    • Export Citation
  • 200

    Package insert. Capecitabine (Xeloda®), Nutley, NJ, Roche Laboratories Inc., June 2005.

  • 201

    Haller DG, Cassidy J, Clarke SJ. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:21182123.

    • Search Google Scholar
    • Export Citation
  • 202

    Schmoll HJ, Arnold D. Update on capecitabine in colorectal cancer. Oncologist 2006;11:10031009.

  • 203

    Package Insert. Irinotecan hydrochloride injection (Camptosar®), New York, NY, Pfizer, June 2006.

  • 204

    Innocenti F, Undevia SD, Iyer L et al. . Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:13821388.

    • Search Google Scholar
    • Export Citation
  • 205

    LabCorp Capsule. UGT1A1 irinotecan toxicity. Managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar, CPT-11). 2006. Available at www.lapcorp.com.

    • Search Google Scholar
    • Export Citation
  • 206

    O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24:45344538.

    • Search Google Scholar
    • Export Citation
  • 207

    Package insert. Oxaliplatin (Eloxatin®), Bedford, OH. Ben Venue Laboratories, November 2004.

  • 208

    Tournigand C, Cervantes A, Figer A et al. . OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 2006;24:394400.

    • Search Google Scholar
    • Export Citation
  • 209

    Maindrault-Goebel F, Lledo G, Ghibaudel B et al. . Final results for OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4013.

    • Search Google Scholar
    • Export Citation
  • 210

    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:12091214.

    • Search Google Scholar
    • Export Citation
  • 211

    Cunningham D, Pyrhonen S, James RD et al. . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:14131418.

    • Search Google Scholar
    • Export Citation
  • 212

    Rougier P, Van Cutsem E, Bajetta E et al. . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:14071412.

    • Search Google Scholar
    • Export Citation
  • 213

    Pitot H, Rowland K, Sargent DJ et al. . N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 3506.

    • Search Google Scholar
    • Export Citation
  • 214

    Saltz LB, Meropol NJ, Loehrer PJ Sr et al. . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:12011208.

    • Search Google Scholar
    • Export Citation
  • 215

    Saltz L, Rubin M, Hochster H et al. . Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol 2001;20:Abstract 7.

    • Search Google Scholar
    • Export Citation
  • 216

    Jonker DJ, O’Callaghan CJ, Karapetis CS et al. . Cetuximab for the treatment of colorectal cancer. J Clin Oncol 2007;357:20402047.

  • 217

    Sobrero AF, Maurel J, Fehrenbacher L et al. . EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:23112319.

    • Search Google Scholar
    • Export Citation
  • 218

    Hecht JR, Mitchell E, Chidiac T et al. . A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672680.

    • Search Google Scholar
    • Export Citation
  • 219

    Package Insert. Cetuximab (Erbitux®), Branchburg, NJ, Imclone Systems, Inc. 2004.

  • 220

    Package Insert. Panitumumab (Vectibix™), Thousand Oaks, CA, Amgen, September 2006.

  • 221

    Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007;18:963964.

    • Search Google Scholar
    • Export Citation
  • 222

    Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529531.

    • Search Google Scholar
    • Export Citation
  • 223

    Berlin J, van Cutsem E, Peeters M et al. . Predictive value of skin toxicity severity for response to panitumumab in pateints with metastatic colorectal cancer: a pooled analysis of five clinical trials [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4134.

    • Search Google Scholar
    • Export Citation
  • 224

    Hecht JR, Mitchell E, Chidiac T et al. . A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672680.

    • Search Google Scholar
    • Export Citation
  • 225

    Tol J, Koopman M, Cats A et al. . Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563572.

  • 226

    Hecht J, Mitchell E, Baranda J et al. . Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth receptor (EGFr) [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 3506.

    • Search Google Scholar
    • Export Citation
  • 227

    Goldberg RM, Kohne GH, Seymour MT et al. . A pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials of 6,286 patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4011.

    • Search Google Scholar
    • Export Citation
  • 228

    Hoff PM, Pazdur R, Lassere Y et al. . Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22:20782083.

    • Search Google Scholar
    • Export Citation
  • 229

    Pietra N, Sarli L, Costi R et al. . Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:11271133.

    • Search Google Scholar
    • Export Citation
  • 230

    Secco GB, Fardelli R, Gianquinto D et al. . Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418423.

    • Search Google Scholar
    • Export Citation
  • 231

    Rodriguez-Moranta F, Salo J, Arcusa A et al. . Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006;24:386393.

    • Search Google Scholar
    • Export Citation
  • 232

    Figueredo A, Charette ML, Maroun J et al. . Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004;22:33953407.

    • Search Google Scholar
    • Export Citation
  • 233

    Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813.

    • Search Google Scholar
    • Export Citation
  • 234

    Jeffery M, Hickey B, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007:CD002200.

    • Search Google Scholar
    • Export Citation
  • 235

    Desch CE, Benson AB III, Somerfield MR et al. . Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:85128519.

    • Search Google Scholar
    • Export Citation
  • 236

    Guyot F, Faivre J, Manfredi S et al. . Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756761.

  • 237

    Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol 2006;15:112.

  • 238

    Pfister DG, Benson AB III, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:23752382.

    • Search Google Scholar
    • Export Citation
  • 239

    Locker GY, Hamilton S, Harris J et al. . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:53135327.

    • Search Google Scholar
    • Export Citation
  • 240

    Rex DK, Kahi CJ, Levin B et al. . Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160167.

    • Search Google Scholar
    • Export Citation
  • 241

    Green RJ, Metlay JP, Propert K et al. . Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261269.

    • Search Google Scholar
    • Export Citation
  • 242

    Sprangers MAG, Taal BG, Aaronson NK et al. . Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum 1995;38:361369.

  • 243

    Denlinger CS, Barsevick AM. The Challenges of Colorectal Cancer Survivorship. J Natl Compr Cancer Netw 2009; in press.

  • 244

    Dignam JL, Polite BN, Yothers G et al. . Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:16471654.

    • Search Google Scholar
    • Export Citation
  • 245

    Meyerhardt JA, Heseltine D, Niedzwiecki D et al. . Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24:35353541.

    • Search Google Scholar
    • Export Citation
  • 246

    Meyerhardt JA, Niedzwiecki D, Hollis D et al. . Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007;298:754764.

    • Search Google Scholar
    • Export Citation
  • 247

    Martin EW Jr., Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985;202:310317.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 6369 3943 280
PDF Downloads 3080 2010 259
EPUB Downloads 0 0 0